About the Authors

Hugh O’Brien

Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing

Affiliation Achilles Therapeutics UK Ltd, United Kingdom

Max Salm

Roles Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing

m.salm@achillestx.com (MS); sirha@dtu.dk (SRH); s.quezada@ucl.ac.uk (SAQ)

Affiliation Achilles Therapeutics UK Ltd, United Kingdom

Laura T. Morton

Roles Conceptualization, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing

Affiliation Achilles Therapeutics UK Ltd, United Kingdom

Maciej Szukszto

Roles Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing

Affiliation Research Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom

Felix O’Farrell

Roles Formal analysis, Methodology, Software, Validation, Writing – original draft, Writing – review & editing

Affiliation Achilles Therapeutics UK Ltd, United Kingdom

Charlotte Boulton

Roles Validation, Visualization, Writing – review & editing

Affiliation Research Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom

Laurence King

Roles Validation, Writing – review & editing

Affiliations Achilles Therapeutics UK Ltd, United Kingdom, Research Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom

Supreet Kaur Bola

Roles Validation, Writing – review & editing

Affiliation Research Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom

Pablo D. Becker

Roles Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing

Affiliation Achilles Therapeutics UK Ltd, United Kingdom

Andrew Craig

Roles Conceptualization, Supervision, Writing – review & editing

Affiliation Achilles Therapeutics UK Ltd, United Kingdom

Morten Nielsen

Roles Data curation, Resources, Software, Writing – review & editing

Affiliation Technical University of Denmark, Lyngby, Denmark

Yardena Samuels

Roles Conceptualization, Funding acquisition, Resources, Supervision, Writing – review & editing

Affiliation Weizmann Institute of Science, Rehovot, Israel

Charles Swanton

Roles Conceptualization, Funding acquisition, Project administration, Resources, Supervision

Affiliation The Francis Crick Institute, London, United Kingdom

Marc R. Mansour

Roles Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing

Affiliations Research Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom, Department of Developmental Biology and Cancer, Great Ormond Street Institute of Child Health, UCL

Sine Reker Hadrup

Roles Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing

m.salm@achillestx.com (MS); sirha@dtu.dk (SRH); s.quezada@ucl.ac.uk (SAQ)

Affiliation Technical University of Denmark, Lyngby, Denmark

Sergio A. Quezada

Roles Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing

m.salm@achillestx.com (MS); sirha@dtu.dk (SRH); s.quezada@ucl.ac.uk (SAQ)

‡ on behalf of the DECOD-Ag Consortium.

Affiliations Achilles Therapeutics UK Ltd, United Kingdom, Research Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom

Competing Interests

I have read the journal’s policy and the authors of this manuscript have the following competing interests: S.A.Q. is co-founder and chief scientific officer and own shares in Achilles Therapeutics. C.S. acknowledges grants from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx Inc., a collaboration in minimal residual disease sequencing technologies), Ono Pharmaceutical and Personalis. He is chief investigator for the AZ MeRmaiD 1 and 2 clinical trials and is the steering committee chair. He is also co-chief investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s scientific advisory board (SAB). He receives consultant fees from Achilles Therapeutics (also an SAB member); Bicycle Therapeutics (also an SAB member); Genentech; Medicxi; the China Innovation Centre of Roche (CICoR), formerly Roche Innovation Centre Shanghai; Metabomed (until July 2022); Relay Therapeutics; and the Sarah Cannon Research Institute. C.S has received honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Illumina, MSD, Novartis, Pfizer and Roche-Ventana; previously held stock options in Apogen Biotechnologies and GRAIL; currently has stock options in Epic Bioscience and Bicycle Therapeutics; and has stock options and is co-founder of Achilles Therapeutics. S.R.H. is the cofounder of PokeAcell and is co-inventor of licensed patents related to T cell detection. H.O’B., M.S., L.M. and F.O’F. are employees of Achilles Therapeutics. H.O’B. and M.S. are both named inventors on patents for ImmugenX.